NeoGenomics, Inc. Launches RaDaR ST MRD Test for Solid Tumors
NeoGenomics launches RaDaR ST, expanding its molecular residual disease (MRD) testing capabilities across multiple solid tumor types. The new circulating tumor DNA (ctDNA) assay strengthens the company’s precision oncology...

